The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and efficacy of tisagenlecleucel (tisa-cel) plus pembrolizumab (pembro) in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL): Updated analysis of the phase 1b PORTIA study.
 
Ulrich Jäger
Honoraria - Abbvie; Celgene/Bristol-Myers Squibb; F. Hoffmann LaRoche; Gilead Sciences; Karyopharm Therapeutics; Miltenyi Biotec; Novartis
Consulting or Advisory Role - CDR-Life; Celgene/Bristol-Myers Squibb; Miltenyi Biotec; Novartis
Research Funding - CDR-Life (Inst); Celgene/Bristol-Myers Squibb (Inst); F. Hoffmann LaRoche (Inst); Gilead Sciences (Inst); Novartis (Inst)
 
Nina Worel
Consulting or Advisory Role - Celgene/Bristol-Myers Squibb; Novartis
Speakers' Bureau - Kite/Gilead; Mallinckrodt/Therakos; Novartis; Sanofi
Research Funding - Sanofi (Inst)
Travel, Accommodations, Expenses - Celgene/Bristol-Myers Squibb; Mallinckrodt/Therakos
 
Joseph McGuirk
Honoraria - AlloVir; Juno Therapeutics; Kite, a Gilead company; Magenta Therapeutics
Consulting or Advisory Role - Allovir; EcoR1 Capital; Juno Therapeutics; Kite, a Gilead company; Magenta Therapeutics
Speakers' Bureau - Kite/Gilead
Research Funding - AlloVir (Inst); Astellas Pharma (Inst); Bellicum Pharmaceuticals (Inst); Fresenius Biotech (Inst); Gamida Cell (Inst); Kite, a Gilead company (Inst); Novartis (Inst); Novartis (Inst); Pluristem Therapeutics (Inst)
Travel, Accommodations, Expenses - Kite, a Gilead company
 
Peter A. Riedell
Honoraria - Novartis
Consulting or Advisory Role - Bayer; BeiGene; Bristol-Myers Squibb/Celgene; Karyopharm Therapeutics; Kite, a Gilead company; Novartis; Takeda; Verastem
Speakers' Bureau - Bayer; Kite, a Gilead company
Research Funding - Bristol-Myers Squibb/Celgene; Calibr; Kite, a Gilead company; MorphoSys; Novartis
 
Isabelle Fleury
Honoraria - Abbvie; Gilead Sciences; Janssen; Novartis; Roche; Seagen
Consulting or Advisory Role - Abbvie; AstraZeneca; Gilead Sciences; Janssen; Novartis; Roche; Seagen
 
Peter Borchmann
No Relationships to Disclose
 
Yan Du
Employment - Novartis
 
Ahmed M. Abdelhady
Employment - Novartis
 
Xia Han
Employment - Incyte (I); Novartis
Stock and Other Ownership Interests - Incyte (I); Novartis
 
Marcela Martinez-Prieto
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Honoraria - Novartis
 
Edmund K. Waller
Employment - Cambium Medical Technologies
Leadership - CAMBIUM MEDICAL TECHNOLOGIES; CAMBIUM MEDICAL TECHNOLOGIES; CAMBIUM MEDICAL TECHNOLOGIES
Stock and Other Ownership Interests - CAMBIUM MEDICAL TECHNOLOGIES; CAMBIUM MEDICAL TECHNOLOGIES; Cerus; Chimerix; Chimerix
Honoraria - Karyopharm Therapeutics; Kite, a Gilead company; Novartis; Partners; Pharmacyclics; Verastem
Consulting or Advisory Role - Karyopharm Therapeutics; Kite, a Gilead company; Novartis; Partners Healthcare; Pharmacyclics; Verastem
Research Funding - Amgen; Juno Therapeutics; Novartis; Partners Healthcare; Partners Healthcare; Verastem
Patents, Royalties, Other Intellectual Property - Receive Royalties from patent on preparing platelet lysate that has been licensed to Cambium Medical Technologies
Travel, Accommodations, Expenses - Pharmacyclics